Clinical trial · Interventional
Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients
RePPAIR -Reducing Procedural Pain and Improving Recovery of Quality of Life in Pediatric Neuroblastoma Patients Undergoing Bone Marrow Procedures: A Prospective Randomized Cross-over Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to identify whether or not the addition of a numbing medicine that is injected directly into the site of the bone marrow procedure can reduce pain and the use of opioid pain medication after bone marrow procedures. The addition of this medicine, called ropivacaine, is the experimental part of this study. This is the first time ropivacaine will be directly injected into the bone marrow site at MSKCC Pediatrics.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroblastoma | Neuroblastoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Post-procedural quality of life (QOL) | Behavioral | — | UNRESOLVED |
| propofol | Device | — | UNRESOLVED |
| ropivacaine | Drug | — | UNRESOLVED |
| Wong-Baker FACES® Pain Rating Scale | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Propofol First, then Propofol & Ropivacaine
- description
- 1st Bone Marrow procedure (BM) Intervention A: propofol first. Then second BM procedure with propofol \& ropivacaine
- interventionNames
- Device: propofol
- Behavioral: Wong-Baker FACES® Pain Rating Scale
- Behavioral: Post-procedural quality of life (QOL)
- type
- EXPERIMENTAL
- label
- Propofol and Ropivacaine First, then Propofol
- description
- 1st BM procedure: Intervention B: propofol \& ropivacaine first. Then second BM procedure with propofol
- interventionNames
- Drug: ropivacaine
- Behavioral: Wong-Baker FACES® Pain Rating Scale
- Behavioral: Post-procedural quality of life (QOL)
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Years
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of neuroblastoma as defined by the International Neuroblastoma Risk Group Staging System (INRGSS)22 * 3 - 18 years of age * Patient has had prior bone marrow procedures * English speaking Exclusion Criteria: * History of allergy to investigational agent: ropivacaine or other amino amide analgesics * History of allergy to standard agent: propofol * Chronic daily opioid requirement * Lansky/Karnofsky Score \< 60 * Inability to comply with protocol requirements including refusal to forego pre-procedural opioid use * Patient is receiving additional potentially painful interventions (e.g. central line insertion/removal) concurrent with the bone marrow procedure
References
Publications (1)
- DERIVEDZarnegar-Lumley S, Lange KR, Mathias MD, Nakajima-Hatano M, Offer KM, Ogu UO, Ortiz MV, Tan KS, Kellick M, Modak S, Roberts SS, Basu EM, Dingeman RS. Local Anesthesia With General Anesthesia for Pediatric Bone Marrow Procedures. Pediatrics. 2019 Aug;144(2):e20183829. doi: 10.1542/peds.2018-3829. PMID 31366683